Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Cardium Therapeutics Inc. (CXM) Regains Listing Compliance With NYSE Amex

Cardium Therapeutics today reported that it had received notice from NYSE Regulation that the Company is now considered to have regained compliance with the listing requirements of the NYSE Amex LLC (formerly the American Stock Exchange).

(Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

In the communication from its listing exchange, Cardium was informed that based upon a review of information provided by the Company and publicly available information, including the Company’s Form 8-K filed on January 3, 2012, the Company has resolved the continued listing deficiencies referenced in the NYSE Amex LLC’s letter dated November 26, 2010, as previously reported.  In addition, the Exchange also indicated that as with the case for all listed issuers, the Company’s continued listing eligibility will continue to be assessed on an ongoing basis and that the Company is subject to the provisions of Section 1009(h) of the NYSE Amex Company Guide, which may be accessed at www.nyse.com/regulation.

Let us hear your thoughts below.

This entry was posted in Cardium Therapeutics Inc. CXM. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *